Results 131 to 140 of about 180,190 (229)

Management and safety of same day bilateral intravitreal anti-VEGF injections in a treat-and-extend regimen. [PDF]

BMC Ophthalmol
Plasencia C, Eschle J, Hatz K.
europepmc   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

One-year clinical outcomes of four-dose induction versus immediate treat-and-extend faricimab regimens in pretreated neovascular age-related macular degeneration. [PDF]

BMC Ophthalmol
Menghini M, Grimaldi G, Paris A, Bachmann LM, Schmid MK.   +4 more
europepmc   +1 more source

Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization. [PDF]

Sci Rep, 2023
Matsumoto H, Hoshino J, Nakamura K, Akiyama H.   +3 more
europepmc   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Five-year Outcome of Aflibercept Administration with “Treat and Extend” for Neovascular Age-Related Macular Degeneration

Clinical Ophthalmology
Iori Wada,1,2 Yuji Oshima,3 Yosuke Fukuda,1 Satomi Shiose,1 Kumiko Kano,1 Keijiro Ishikawa,1 Shintaro Nakao,4 Yoshihiro Kaizu,1,5 Eiichi Hasegawa,1,2 Ram Kannan,6,7 Tatsuro Ishibashi,1 Koh-Hei Sonoda1 1Department of Ophthalmology, Graduate School of ...
Wada I, Oshima Y, Fukuda Y, Shiose S, Kano K, Ishikawa K, Nakao S, Kaizu Y, Hasegawa E, Kannan R, Ishibashi T, Sonoda KH   +11 more
doaj  

Five-year Outcome of Aflibercept Administration with "Treat and Extend" for Neovascular Age-Related Macular Degeneration. [PDF]

Clin Ophthalmol
Wada I, Oshima Y, Fukuda Y, Shiose S, Kano K, Ishikawa K, Nakao S, Kaizu Y, Hasegawa E, Kannan R, Ishibashi T, Sonoda KH.   +11 more
europepmc   +1 more source

Comparison of 24-month treatment outcomes between as-needed treatment and switching to treat-and-extend in type 3 macular neovascularization. [PDF]

Sci Rep, 2022
Kim JH, Kim JW, Kim CG.
europepmc   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Treatment Cessation in Patients with Diabetic Maculopathy under Intravitreal Anti-VEGF Therapy Following a Treat-and-Extend Protocol. [PDF]

Ophthalmol Sci
Saucedo L, Pfister IB, Schild C, Garweg JG.   +3 more
europepmc   +1 more source